Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
The sustained success of Eliquis is further supported by its patent protections, which have delayed generic competition in the US until at least 2026, and potentially until 2031
Prevnar family (pneumococcal 13-valent conjugate vaccine) Disease area(s): Vaccines/infectious diseases Manufacturer(s): Pfizer 2024 Sales (USD): $6.41 billion Why it sold so well: In 2024, Pfizers Prevnar family of pneumococcal vaccines generated $6.4 billion in global revenue, accounting for 10% of the companys total revenue and ranking as its second-highest-selling product after Eliquis
Semax came off the Category 2 list in 2026 and is also one of the seven peptides under PCAC review in July 2026
The 15mg group achieved 22.5% weight loss
Sleep hygiene improvements often reduce headache susceptibility
US$ 27.18
US$ 24.03
US$ 23.25
